A A Amin1, R W Snow, G O Kokwaro. 1. Centre for Geographic Medicine, Kenya Medical Research Institute/Wellcome Trust Collaborative Programme, Nairobi, Kenya. aamin@wtnairobi.mimcom.net
Abstract
BACKGROUND AND OBJECTIVE: Malaria is a disease of major public health importance in Kenya killing 26,000 children under 5 years of age annually. This paper seeks to assess the quality of sulphadoxine-pyrimethamine (SP) and amodiaquine (AQ) products available over-the-counter to communities in Kenya as most malaria fevers are self-medicated using drugs from the informal retail sector. METHODS: A retail audit of 880 retail outlets was carried in 2002 in four districts in Kenya, in which antimalarial drug stocks and their primary wholesale sources were noted. In addition, the expiry dates on audited products and the basic storage conditions were recorded on a proforma. The most commonly stocked SP and AQ products were then sampled from the top 10 wholesalers in each district and samples subjected to standard United States Pharmacopoeia (USP) tests of content and dissolution. RESULTS AND DISCUSSION: SP and AQ were the most frequently stocked antimalarial drugs, accounting for approximately 75% of all the antimalarial drugs stocked in the four districts. Of 116 SP and AQ samples analysed, 47 (40.5%) did not meet the USP specifications for content and/or dissolution. Overall, approximately 45.3% of SP and 33.0% of AQ samples were found to be sub-standard. Of the sub-standard SP products, 55.2% were suspensions while 61.1% of the substandard AQ products were tablets. Most SP failures were because of the pyrimethamine component. CONCLUSION: There is a need to strengthen post-marketing surveillance systems to protect patients from being treated with sub-standard and counterfeit antimalarial drugs in Kenya.
BACKGROUND AND OBJECTIVE:Malaria is a disease of major public health importance in Kenya killing 26,000 children under 5 years of age annually. This paper seeks to assess the quality of sulphadoxine-pyrimethamine (SP) and amodiaquine (AQ) products available over-the-counter to communities in Kenya as most malaria fevers are self-medicated using drugs from the informal retail sector. METHODS: A retail audit of 880 retail outlets was carried in 2002 in four districts in Kenya, in which antimalarial drug stocks and their primary wholesale sources were noted. In addition, the expiry dates on audited products and the basic storage conditions were recorded on a proforma. The most commonly stocked SP and AQ products were then sampled from the top 10 wholesalers in each district and samples subjected to standard United States Pharmacopoeia (USP) tests of content and dissolution. RESULTS AND DISCUSSION: SP and AQ were the most frequently stocked antimalarial drugs, accounting for approximately 75% of all the antimalarial drugs stocked in the four districts. Of 116 SP and AQ samples analysed, 47 (40.5%) did not meet the USP specifications for content and/or dissolution. Overall, approximately 45.3% of SP and 33.0% of AQ samples were found to be sub-standard. Of the sub-standard SP products, 55.2% were suspensions while 61.1% of the substandard AQ products were tablets. Most SP failures were because of the pyrimethamine component. CONCLUSION: There is a need to strengthen post-marketing surveillance systems to protect patients from being treated with sub-standard and counterfeit antimalarial drugs in Kenya.
Authors: P C Kayumba; P G Risha; D Shewiyo; A Msami; G Masuki; D Ameye; G Vergote; J D Ntawukuliryayo; J P Remon; C Vervaet Journal: J Clin Pharm Ther Date: 2004-08 Impact factor: 2.512
Authors: J Singh; A K Dutta; S Khare; N K Dubey; A K Harit; N K Jain; T C Wadhwa; S R Gupta; A C Dhariwal; D C Jain; R Bhatia; J Sokhey Journal: Bull World Health Organ Date: 2003-09-18 Impact factor: 9.408
Authors: P Newton; S Proux; M Green; F Smithuis; J Rozendaal; S Prakongpan; K Chotivanich; M Mayxay; S Looareesuwan; J Farrar; F Nosten; N J White Journal: Lancet Date: 2001-06-16 Impact factor: 79.321
Authors: Sivong Sengaloundeth; Michael D Green; Facundo M Fernández; Ot Manolin; Khamlieng Phommavong; Vongsavanh Insixiengmay; Christina Y Hampton; Leonard Nyadong; Dallas C Mildenhall; Dana Hostetler; Lamphet Khounsaknalath; Latsamy Vongsack; Samlane Phompida; Viengxay Vanisaveth; Lamphone Syhakhang; Paul N Newton Journal: Malar J Date: 2009-07-28 Impact factor: 2.979
Authors: Yvonne Rowa; Timothy O Abuya; Wilfred K Mutemi; Sam Ochola; Sassy Molyneux; Vicki Marsh Journal: BMC Public Health Date: 2010-02-24 Impact factor: 3.295
Authors: Victor S Pribluda; Adrian Barojas; Arletta Añez; Cecilia G López; Ruth Figueroa; Roxana Herrera; Gladys Nakao; Fernando Ha Nogueira; Gerson A Pianetti; Marinete M Povoa; Giselle Mr Viana; Margarete S Mendonça Gomes; Jose P Escobar; Olga L Muñoz Sierra; Susana P Rendon Norena; Raúl Veloz; Marcy Silva Bravo; Martha R Aldás; Alison Hindssemple; Marilyn Collins; Nicolas Ceron; Karanchand Krishnalall; Malti Adhin; Gustavo Bretas; Nelly Hernandez; Marjorie Mendoza; Abdelkrim Smine; Kennedy Chibwe; Patrick Lukulay; Lawrence Evans Journal: Malar J Date: 2012-06-15 Impact factor: 2.979
Authors: Fredrick L Eyase; Hoseah M Akala; Luiser Ingasia; Agnes Cheruiyot; Angela Omondi; Charles Okudo; Dennis Juma; Redemptah Yeda; Ben Andagalu; Elizabeth Wanja; Edwin Kamau; David Schnabel; Wallace Bulimo; Norman C Waters; Douglas S Walsh; Jacob D Johnson Journal: PLoS One Date: 2013-05-13 Impact factor: 3.240